SEC filing record
Primary Source · SEC.gov

Vertical Longevity Pharmaceuticals, Inc.

Platform / Operating Company2025 vintageRegulation CF (4(a)(6))
Latest signalNew Form D filerForm D · 2026-09-284 events: 1 new form d filer, 1 reg cf reporting terminated, 1 reg cf annual reportLast filing 2026-09-28

Raised

Pre-close

Target

$500K

Deadline

Jan 2026

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

AltStreet Analysis

·

Generated from EDGAR primary sources

Vertical Longevity Pharmaceuticals, Inc. is a Delaware corporation incorporated in March 2025, offering common stock at $0.97 per share with a target raise of $10K and maximum of $500K, deadline January 16, 2026, via NetCapital Funding Portal Inc. The issuer reports zero revenue, net income, total assets, cash, and long-term debt for its most recent fiscal year (unaudited), consistent with a pre-revenue early-stage venture. The company employs 2 people at filing.

This Regulation Crowdfunding offering is typical of early-stage operating company raises on portal platforms, enabling retail investor access to private equity at small scale. The $10K-$500K range falls well within Reg CF norms, with NetCapital acting as the SEC-registered intermediary.

Data Flags

Zero total assets reported
Very low target raise

Critical Disclosures

What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.

Reporting terminated · Form C · last filing April 27, 2026

Form C-TR filed: reporting terminated

Timeline
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer

EDGAR Filing Data

Form C — Primary Source

View on SEC.gov
CIK Number0002087846
Entity NameVertical Longevity Pharmaceuticals, Inc.
ExemptionRegulation CF (4(a)(6))
Securities TypeEquity
First Sale Date—
Filing DateOctober 10, 2025
Accession Number0001669191-25-000512
Total Amount Sold—
Total Investors—
Minimum Investment$0 (no stated minimum)
State (Issuer Address)56 US jurisdictions
Amendment Count4 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

4

latest Sep 28, 2026

Critical / warning

0 / 0

1 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

terminated, closed

Latest event New filer · Sep 28, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 4 filing events with values and deltas, latest 2026-09-28, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

David Scieszka

Principal Executive Officer

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.